

WEST[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 15 of 15 returned.**☐ 1. Document ID: US 20030039675 A1

L3: Entry 1 of 15

File: PGPB

Feb 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030039675

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030039675 A1

TITLE: Therapeutic inhibitor of vascular smooth muscle cells

PUBLICATION-DATE: February 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kunz, Lawrence L.	Redmond	WA	US	
Reno, John M.	Brier	WA	US	

US-CL-CURRENT: 424/423; 514/449, 514/720

ABSTRACT:

Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC
Draw Desc	Image										

☐ 2. Document ID: US 20020086896 A1

L3: Entry 2 of 15

File: PGPB

Jul 4, 2002

PGPUB-DOCUMENT-NUMBER: 20020086896

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020086896 A1

TITLE: Therapeutic inhibitor of vascular smooth muscle cells

PUBLICATION-DATE: July 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kunz, Lawrence L.	Redmond	WA	US	
Klein, Richard A.	Edmonds	WA	US	
Reno, John M.	Brier	WA	US	

US-CL-CURRENT: 514/449; 514/411

ABSTRACT:

Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC
Draw Desc	Image										

☐ 3. Document ID: US 20020025979 A1

L3: Entry 3 of 15

File: PGPB

Feb 28, 2002

PGPUB-DOCUMENT-NUMBER: 20020025979

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020025979 A1

TITLE: Therapeutic inhibitor of vascular smooth muscle cells

PUBLICATION-DATE: February 28, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kunz, Lawrence L.	Redmond	WA	US	
Reno, John M.	Brier	WA	US	

US-CL-CURRENT: 514/411

ABSTRACT:

Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC
Draw Desc	Image										

☒ 4. Document ID: US 20020022716 A1

L3: Entry 4 of 15

File: PGPB

Feb 21, 2002

PGPUB-DOCUMENT-NUMBER: 20020022716
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020022716 A1

TITLE: High throughput sarcomeric assay

PUBLICATION-DATE: February 21, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Hartman, James J.	San Francisco	CA	US	
Malik, Fady	Burlingame	CA	US	
Sakowicz, Roman	Foster City	CA	US	
Finer, Jeffrey T.	Foster City	CA	US	

US-CL-CURRENT: 530/353; 530/355

ABSTRACT:

The present invention provides high throughput screening systems for identifying compounds that modulate the biological activity of a biochemically functional sarcomere. The method can be performed in plurality simultaneously with fluorescence or absorbance readouts.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

K00C

☐ 5. Document ID: US 20010051335 A1

L3: Entry 5 of 15

File: PGPB

Dec 13, 2001

PGPUB-DOCUMENT-NUMBER: 20010051335
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20010051335 A1

TITLE: POLYNUCLEOTIDES AND POLYPEPTIDES DERIVED FROM CORN TASSEL

PUBLICATION-DATE: December 13, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
LALGUDI, RAGHUNATH V.	CLAYTON	MO	US	
ITO, LAURA Y.	PLEASANTON	CA	US	
SHERMAN, BRADLEY K.	OAKLAND	CA	US	

US-CL-CURRENT: 435/6; 435/69.1

ABSTRACT:

The present invention provides purified, corn tassel-derived polynucleotides (cdps) which encode corn tassel-derived polypeptides (CDPs). The invention also provides for the use of cdps or their complements, oligonucleotides, or fragments in methods for determining altered gene expression, to recover regulatory elements, and to follow inheritance of desirable characteristics through hybrid breeding programs. The

invention further provides for vectors and host cells containing cdps for the expression of CDPs. The invention additionally provides for (i) use of isolated and purified CDPs to induce antibodies and to screen libraries of compounds and (ii) use of anti-CDP antibodies in diagnostic assays.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KMC

☐ 6. Document ID: US 6569441 B2

L3: Entry 6 of 15

File: USPT

May 27, 2003

US-PAT-NO: 6569441

DOCUMENT-IDENTIFIER: US 6569441 B2

TITLE: Therapeutic inhibitor of vascular smooth muscle cells

DATE-ISSUED: May 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kunz; Lawrence L.	Redmond	WA		
Reno; John M.	Brier	WA		

US-CL-CURRENT: 424/423, 604/104, 604/507, 604/508, 604/890.1, 604/891.1, 604/96.01,
606/108, 606/159, 606/191

ABSTRACT:

Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.

10 Claims, 30 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 22

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KMC

☐ 7. Document ID: US 6509167 B1

L3: Entry 7 of 15

File: USPT

Jan 21, 2003

US-PAT-NO: 6509167

DOCUMENT-IDENTIFIER: US 6509167 B1

TITLE: High throughput sarcomeric assay

DATE-ISSUED: January 21, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hartman; James J.	San Francisco	CA		
Malik; Fady	Burlingame	CA		
Sakowicz; Roman	Foster City	CA		
Finer; Jeffrey T.	Foster City	CA		

US-CL-CURRENT: 435/19; 424/9.2, 435/21, 435/29

ABSTRACT:

The present invention provides high throughput screening systems for identifying compounds that modulate the biological activity of a biochemically functional sarcomere. The method can be performed in plurality simultaneously with fluorescence or absorbance readouts.

12 Claims, 3 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KMC

☐ 8. Document ID: US 6495337 B1

L3: Entry 8 of 15

File: USPT

Dec 17, 2002

US-PAT-NO: 6495337

DOCUMENT-IDENTIFIER: US 6495337 B1

TITLE: High throughput sarcomeric assay

DATE-ISSUED: December 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hartman; James J.	San Francisco	CA		
Malik; Fady	Burlingame	CA		
Sakowicz; Roman	Foster City	CA		
Finer; Jeffrey T.	Foster City	CA		

US-CL-CURRENT: 435/19; 424/9.2, 435/21, 435/29

ABSTRACT:

The present invention provides high throughput screening systems for identifying compounds that modulate the biological activity of a biochemically functional sarcomere. The method can be performed in plurality simultaneously with fluorescence or absorbance readouts.

11 Claims, 3 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

K00C

☐ 9. Document ID: US 6491938 B2

L3: Entry 9 of 15

File: USPT

Dec 10, 2002

US-PAT-NO: 6491938

DOCUMENT-IDENTIFIER: US 6491938 B2

TITLE: Therapeutic inhibitor of vascular smooth muscle cells

DATE-ISSUED: December 10, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kunz; Lawrence L.	Redmond	WA		
Reno; John M.	Brier	WA		

US-CL-CURRENT: 424/423; 435/975, 604/890.1, 604/891.1

ABSTRACT:

Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.

18 Claims, 30 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 21

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

K00C

☐ 10. Document ID: US 6358989 B1

L3: Entry 10 of 15

File: USPT

Mar 19, 2002

US-PAT-NO: 6358989

DOCUMENT-IDENTIFIER: US 6358989 B1

TITLE: Therapeutic inhibitor of vascular smooth muscle cells

DATE-ISSUED: March 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kunz; Lawrence L.	Redmond	WA		
Klein; Richard A.	Edmonds	WA		
Reno; John M.	Brier	WA		

US-CL-CURRENT: 514/411; 424/402, 424/423, 424/443, 424/445, 424/446, 424/447,
604/890.1, 604/891.1

ABSTRACT:

Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.

20 Claims, 30 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 22

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KMJC

☐ 11. Document ID: US 6306421 B1

L3: Entry 11 of 15

File: USPT

Oct 23, 2001

US-PAT-NO: 6306421

DOCUMENT-IDENTIFIER: US 6306421 B1

**** See image for Certificate of Correction ****

TITLE: Therapeutic inhibitor of vascular smooth muscle cells

DATE-ISSUED: October 23, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kunz; Lawrence L.	Redmond	WA		
Reno; John M.	Brier	WA		

US-CL-CURRENT: 424/423; 424/424, 424/425, 514/411, 514/429, 514/449, 514/773

ABSTRACT:

Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.

36 Claims, 30 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 22

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KMJC

☐ 12. Document ID: US 6143875 A

L3: Entry 12 of 15

File: USPT

Nov 7, 2000

US-PAT-NO: 6143875

DOCUMENT-IDENTIFIER: US 6143875 A

TITLE: Antibody to DNase involved in apoptosis

DATE-ISSUED: November 7, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Tanuma; Sei-ichi	Hachioji-shi, Tokyo	192-03		JP

US-CL-CURRENT: 530/387.9; 530/388.1, 530/388.26, 530/389.1

ABSTRACT:

The present invention relates to novel DNases .alpha., .beta. and .gamma. capable of selectively cleaving the linker sites of chromatin DNA. The present invention also relates to novel DNase .gamma. involved in fragmentation of chromatin DNA in apoptosis. The present invention further relates to amino acid sequence of DNase .gamma., DNA encoding said enzyme, nucleotide sequence of said DNA, recombinant vector containing said DNA, transformant containing said recombinant vector, production method of DNase .gamma. comprising culture of said transformant, and antibody having affinity for said DNase .gamma., precursor thereof and the amino acid sequence of fragments thereof. The DNase .gamma. of the present invention takes part in the control system of apoptosis, and effectively contributes to the development of medications for the prevention, treatment and diagnosis of apoptosis-inhibitory or promotive diseases such as cancer, autoimmune diseases and viral infections. In addition, the DNases .alpha. and .beta. of the present invention increase upon viral infection to cleave viral DNA, and are useful for the development of therapeutic agents for viral infections.

1 Claims, 21 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 11

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KIMC

☐ 13. Document ID: US 5981568 A

L3: Entry 13 of 15

File: USPT

Nov 9, 1999

US-PAT-NO: 5981568

DOCUMENT-IDENTIFIER: US 5981568 A

**** See image for Certificate of Correction ****

TITLE: Therapeutic inhibitor of vascular smooth muscle cells

DATE-ISSUED: November 9, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kunz; Lawrence L.	Redmond	WA		
Klein; Richard A.	Edmonds	WA		
Reno; John M.	Brier	WA		

US-CL-CURRENT: 514/411; 514/319, 514/324, 514/422, 514/428, 514/499

ABSTRACT:

Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.

56 Claims, 30 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 22

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMCL
Draw Desc	Image									

☐ 14. Document ID: US 5741648 A

L3: Entry 14 of 15

File: USPT

Apr 21, 1998

US-PAT-NO: 5741648

DOCUMENT-IDENTIFIER: US 5741648 A

**** See image for Certificate of Correction ****

TITLE: Cell analysis method using quantitative fluorescence image analysis

DATE-ISSUED: April 21, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hemstreet, III; George P.	Oklahoma City	OK		
Hurst; Robert E.	Oklahoma City	OK		
Bonner; Rebecca B.	Oklahoma City	OK		
Rao; Jian Yu	Edmond	OK		

US-CL-CURRENT: 435/6; 435/7.21, 435/7.23, 436/63, 436/64, 436/813

ABSTRACT:

A system for evaluating one or more biochemical markers for evaluating individual cancer risk, cancer diagnosis and for monitoring therapeutic effectiveness and cancer recurrence, particularly of bladder cancer. The system uses automated quantitative fluorescence image analysis of a cell sample collected from a body organ. Cells are treated with a fixative solution which inhibits crystal formation. Cell images are selected and stored as grey level images for further analysis. Cell images may be corrected for autofluorescence using a novel autofluorescence correction method. A neural net computer may be used to distinguish true-positive images from false-positive images to improve accuracy of cancer risk assessment. Cells having images positive for a marker may be compared to threshold quantities related to

predetermined cancer risk.

39 Claims, 31 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 24

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KMIC

☐ 15. Document ID: US 5733721 A

L3: Entry 15 of 15

File: USPT

Mar 31, 1998

US-PAT-NO: 5733721

DOCUMENT-IDENTIFIER: US 5733721 A

**** See image for Certificate of Correction ****

TITLE: Cell analysis method using quantitative fluorescence image analysis

DATE-ISSUED: March 31, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hemstreet, III; George P.	Oklahoma City	OK		
Hurst; Robert E.	Oklahoma City	OK		
Bonner; Rebecca B.	Oklahoma City	OK		
Rao; Jian Yu	Edmond	OK		

US-CL-CURRENT: 435/6; 382/133, 435/7.23, 435/968, 435/973, 436/800, 436/805

ABSTRACT:

A system for evaluating one or more biochemical markers for evaluating individual cancer risk, cancer diagnosis and for monitoring therapeutic effectiveness and cancer recurrence, particularly of bladder cancer. The system uses automated quantitative fluorescence image analysis of a cell sample collected from a body organ. Cells are treated with a fixative solution which inhibits crystal formation. Cell images are selected and stored as grey level images for further analysis. Cell images may be corrected for autofluorescence using a novel autofluorescence correction method. A neural net computer may be used to distinguish true-positive images from false-positive images to improve accuracy of cancer risk assessment. Cells having images positive for a marker may be compared to threshold quantities related to predetermined cancer risk.

143 Claims, 31 Drawing figures
Exemplary Claim Number: 143
Number of Drawing Sheets: 24

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KMIC

Generate Collection

Print

Term	Documents
CRYSTALS	0
CRYSTAL.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	708410
CRYSTALA.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	6
CRYSTALAB.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	5
CRYSTALAB-INC.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	1
CRYSTALAC.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	2
CRYSTALAGRAPHIC.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	2
CRYSTALAI.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	1
CRYSTALAIRE.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	1
CRYSTALAKE.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	1
CRYSTALALINE.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	1
(L1 AND CRYSTALS).USPT,PGPB,JPAB,EPAB,DWPI,TDBD.	15

[There are more results than shown above. Click here to view the entire set.](#)

Display Format:

[Previous Page](#) [Next Page](#)